The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS

Documenti analoghi

• The incidence of serious bleeding events in a global, single-arm, open-label trial of Drotrecogin alfa (activated) in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
  di: Beale, R, et al.
  Pubblicazione: (2004)
• Drotrecogin alfa (activated) in the subgroup of patients with multiple organ dysfunction (MOD) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
  di: Vincent, J, et al.
  Pubblicazione: (2004)
• Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
  di: Levy, Howard, et al.
  Pubblicazione: (2005)
• Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis
  di: Laterre, Pierre-François, et al.
  Pubblicazione: (2008)
• Early treatment with Drotrecogin alfa (activated) was associated with reduced hospital resource use in adult severe sepsis patients with an APACHE II score of 25 or greater at baseline: results from ENHANCE
  di: Doig, C, et al.
  Pubblicazione: (2004)